SCHEMBL5352377

SCHEMBL5352377

COCOC(CCNS(=O)(=O)c1ccsc1C(=O)O)c1ccc(F)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.39
MAPT P10636 1/20 0.39
KMT2A Q03164 2/20 0.37
MEN1 O00255 1/20 0.37
CYP3A4 P08684 1/20 0.37
TSHR P16473 1/20 0.37
LMNA P02545 2/20 0.37
EDNRA P25101 3/20 0.36
FABP4 P15090 4/20 0.36
KCNH2 Q12809 1/20 0.35
KDM4E B2RXH2 1/20 0.35
USP2 O75604 1/20 0.34
ALDH1A1 P00352 2/20 0.34
CYP1A2 P05177 1/20 0.34
CYP2D6 P10635 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
HTT P42858 2/20 0.34
TP53 P04637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5358993 0.92 KCNH2 (0.41) SMN1; SMN2MAPTKMT2AMEN1LMNA
SCHEMBL5358765 0.82 SMN1; SMN2 (0.34) SMN1; SMN2MAPTLMNAUSP2
SCHEMBL5352376 0.80 LMNA (0.38) SMN1; SMN2MAPTLMNAFABP4ALDH1A1
SCHEMBL5354260 0.76 KCNH2 (0.45) SMN1; SMN2MAPTKMT2AMEN1LMNA
SCHEMBL5356271 0.74 TAAR1 (0.50) SMN1; SMN2KMT2AMEN1CYP3A4TSHR
SCHEMBL5358989 0.73 LMNA (0.44) SMN1; SMN2MAPTLMNAKCNH2ALDH1A1
SCHEMBL5359290 0.70 CYP3A4 (0.34) SMN1; SMN2CYP3A4ALDH1A1CYP2C19NPSR1
SCHEMBL5354487 0.69 ALDH1A1 (0.54) SMN1; SMN2MAPTLMNAEDNRAKCNH2
SCHEMBL5358758 0.67 MAPT (0.36) SMN1; SMN2MAPTKMT2AMEN1LMNA
SCHEMBL5361944 0.65 AOC3 (0.45) SMN1; SMN2MAPTKMT2AMEN1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7217723-B2 Substituted benzothiophenes, e.g., 7Z)-7-hydroxyimino-4,5,6,7-tetrahydro-benzo[b]thiophene-3-sulfonic acid [2-(4-fluorophenyl)-2-hydroxyethyl]-methyl-amide; treating allergies such as atopic dermatitis, allergic coryza, bronchial asthma, hypersensitive pneumoniac and pulmonary aspergillosis. EISAI CO., LTD. (JP) 2007-05-15 US disclosed
US-20050227959-A1 Heterocyclic compound having oxime group EISAI CO., LTD. (JP) 2005-10-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050227959-A1 Heterocyclic compound having oxime group STAT6, HRH4, HRH2 SMN1; SMN2 4036/4885MAPT 4554/4885KMT2A 649/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.